Overview

Brain Mets - Capecitabine Plus Sunitinib and WBRT

Status:
Terminated

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Baylor Breast Care Center

Treatments:

Capecitabine
Sunitinib